Pfizer Inc. (PFE)
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Pfizer's drug for advanced lung cancer shows promising long-term trial results
Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which could help establish it as the new standard treatment for the condition. Lorbrena is already approved in the U.S. for treating adults with advanced non-small cell lung cancer who have a mutation in a gene called ALK.
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Pfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the strength of data presented on Friday showing most patients treated for a rare form of advanced lung cancer in a clinical trial were alive without the disease worsening after five years.
EU regulator recommends use of Pfizer's gene therapy for rare bleeding disorder
The European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding disorder called hemophilia B, which typically requires regular infusions of a blood-clotting protein, the regulator said on Friday.
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Pfizer's dividend yield is rising as the stock price is falling.
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2 Beaten-Down Dividend Stocks Near 52-Week Lows. Should You Buy the Dips?
Investors looking for dividend stocks have probably noticed Pfizer and Walgreens Boots Alliance offer above-average yields. Walgreens Boots Alliance stock is under pressure after shutting down an initiative that would have made it more than just a retail pharmacy chain.
Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe?
A monthly chart of PFE using Worden's TC2000 Gold shows the stock oversold on a monthly basis. A stock with a 5.8-6% dividend yield in today's market immediately draws attention. Is the dividend sustainable, and will the pharma giant be able to sustain the current $0.42 per quarter ($1.68 per year) dividend pace and also continue to boost that dividend at a $0.04 per year (one penny per quarter) rate?
Pfizer: Turning The Corner (Rating Upgrade)
Pfizer's stock has hit bottom and could see a boost from bird flu fears. Covid-related sales now account for less than 15% of Pfizer's total revenues, de-risking the investment story. Pfizer is cutting $4 billion in annual costs and has raised its EPS target for the year.
How Much Will Pfizer Pay Out in Dividends This Year?
Pfizer sells more innovative new medicines than any of its peers. Pfizer has raised its dividend payout every year since 2009.
1 No-Brainer Dividend Stock Yielding More Than 5% to Buy and Hold Forever
Pfizer's revenue and net income are moving in the wrong direction. However, the drugmaker has been rejuvenating its pipeline.
